Christopher G. Willett mostly deals with Surgery, Internal medicine, Radiation therapy, Colorectal cancer and Oncology. His Surgery study incorporates themes from Neoadjuvant therapy, Cancer and Carcinoma. His Internal medicine study which covers Gastroenterology that intersects with Adjuvant.
His work deals with themes such as Chemotherapy, Adjuvant therapy, Survival rate, Rectum and Randomized controlled trial, which intersect with Radiation therapy. His research in Colorectal cancer intersects with topics in Bevacizumab and MEDLINE. His research investigates the connection with Oncology and areas like Disease which intersect with concerns in Perioperative, General surgery, Systemic therapy, Immunology and Antiangiogenic therapy.
Radiation therapy, Internal medicine, Oncology, Surgery and Colorectal cancer are his primary areas of study. Christopher G. Willett has included themes like Cancer, Chemotherapy and Rectum in his Radiation therapy study. Many of his studies on Internal medicine apply to Gastroenterology as well.
Christopher G. Willett usually deals with Oncology and limits it to topics linked to Capecitabine and Oxaliplatin. The Surgery study combines topics in areas such as Carcinoma and Adenocarcinoma. Christopher G. Willett works mostly in the field of Colorectal cancer, limiting it down to topics relating to Disease and, in certain cases, General surgery, as a part of the same area of interest.
Christopher G. Willett focuses on Internal medicine, Oncology, Colorectal cancer, Radiation therapy and Cancer. His Internal medicine study typically links adjacent topics like Gastroenterology. His Oncology research incorporates elements of Gemcitabine, Locally advanced, Chemotherapy, Randomized controlled trial and Esophageal cancer.
His studies deal with areas such as Neoadjuvant therapy, Combined Modality Therapy, Disease and General surgery as well as Colorectal cancer. He combines subjects such as Clinical trial and Rectal Adenocarcinoma with his study of Radiation therapy. His Cancer research includes elements of Proportional hazards model and Lymph node, Pathology.
The scientist’s investigation covers issues in Internal medicine, Oncology, Colorectal cancer, Disease and Radiation therapy. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Bioinformatics. His work carried out in the field of Oncology brings together such families of science as Cancer, Esophageal cancer, Adenocarcinoma and Chemotherapy.
He interconnects Neoadjuvant therapy and General surgery in the investigation of issues within Colorectal cancer. His Disease research includes themes of Combined Modality Therapy, Perioperative, Systemic therapy and MEDLINE. His specific area of interest is Radiation therapy, where Christopher G. Willett studies Chemoradiotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda.
Nature Medicine (2004)
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
Carolyn C. Compton;L. Peter Fielding;Lawrence J. Burgart;Barbara Conley.
Archives of Pathology & Laboratory Medicine (2000)
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
Joel Tepper;Mark J. Krasna;Donna Niedzwiecki;Donna Hollis.
Journal of Clinical Oncology (2008)
Prognostic Factors in Colorectal Cancer
Carolyn C. Compton;Carolyn C. Compton;L. Peter Fielding;Lawrence J. Burgart;Barbara Conley.
Archives of Pathology & Laboratory Medicine (2000)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
William F. Regine;Kathryn A. Winter;Ross A. Abrams;Howard Safran.
Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial
Jaffer A. Ajani;Kathryn A. Winter;Leonard L. Gunderson;John Pedersen.
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan.
Journal of The National Comprehensive Cancer Network (2017)
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
Engstrom Pf;Arnoletti Jp;Benson Ab rd;Chen Yj.
Journal of The National Comprehensive Cancer Network (2009)
Biomarkers of response and resistance to antiangiogenic therapy.
Rakesh K. Jain;Dan G. Duda;Christopher G. Willett;Dushyant V. Sahani.
Nature Reviews Clinical Oncology (2009)
Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer
David P. Kelsen;Katryn A. Winter;Leonard L. Gunderson;Joanne Mortimer.
Journal of Clinical Oncology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: